Details of the Drug Combination

General Information of Drug Combination (ID: DCTMP0Y)

Drug Combination Name
Salicylhydroxamic acid Aflibercept
Indication
Disease Entry Status REF
Neovascular Age-related Macular Degeneration Phase 2 [1]
Component Drugs Salicylhydroxamic acid   DMGLSPC Aflibercept   DMT3D5I
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Salicylhydroxamic acid
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
Salicylhydroxamic acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Aflibercept
Disease Entry ICD 11 Status REF
Central retinal vein occlusion with macular edema N.A. Approved [3]
Diabetic macular edema 9B71.02 Approved [4]
Exudative age-related macular degeneration 9B78.3Z Approved [5]
Metastasis from malignant tumor of colon N.A. Approved [6]
Metastatic colorectal cancer 2B91 Approved [7]
Aflibercept Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [7]
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Modulator [7]
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Exudative Age-related Macular Degeneration DC9QBQT N. A. Phase 2 [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04684394) A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
2 Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
3 A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
4 Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
5 Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
6 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e323-e328.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 ClinicalTrials.gov (NCT04200248) A Phase II Study of RBM-007 Alone and RBM-007 With Eylea in Subjects With Wet Age-related Macular Degeneration